Asset Details
Do you wish to reserve the book?
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models
Do you wish to request the book?
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models
2025
Overview
Background
Chimeric antigen receptor (CAR) engineered natural killer (NK) cells have shown their efficacy and superiority against cancer and possess the potential to become off-the-shelf immunotherapy products. Nonetheless, some challenges associated with CAR-NK cells still exist including inhibitory receptor engagement, antigen escape, and inadequate activation.
Methods
Given this, based on the concept of synthetic biology, we rationally designed a novel dual-targeted CAR (dtCAR), primarily comprising PD-L1 nanoantibody (PD-L1
Nb
) and NKG2D as the ectodomain, transmembrane and cytoplasmic domains (CP) of CD28, and the CP of 4-1BB and CD3ζ. NK92 cells were engineered to express this third-generation of dtCAR. We then elucidated the role of dtCAR-modified NK92 cells against cancer cells in vitro and in vivo.
Results
In vitro, the dtCAR-NK92 cells could still retain the characteristics of parental NK cells and exhibit improved NK cell cytotoxicity and produce more cytokines than NK92 cells when they were co-cultured with human lung cancer H1299 cells. Notably, the dtCAR-NK92 cell therapy might elicit clearance of H1299 cells by pyroptosis. Additionally, dtCAR-NK92 cells could considerably inhibit tumor growth in the human lung cancer H1299 cell tumor model.
Conclusions
We confirmed that expression of dtCAR enhanced NK92-cell activation and killing in vitro and in vivo, which provides a novel immunotherapeutic strategy for using NK-tailored CAR-engineered NK92 cells to treat human lung cancer.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Animals
/ Antigens
/ B7-H1 Antigen - antagonists & inhibitors
/ Biomedical and Life Sciences
/ Cancer
/ Cells
/ Health Promotion and Disease Prevention
/ Histocompatibility Antigens Class I - immunology
/ Humans
/ Immunotherapy, Adoptive - methods
/ Killer Cells, Natural - immunology
/ Killer Cells, Natural - metabolism
/ Killer Cells, Natural - transplantation
/ Mice
/ NK Cell Lectin-Like Receptor Subfamily K - immunology
/ NK cells
/ NKG2D
/ Oncology
/ Receptors, Chimeric Antigen - genetics
/ Receptors, Chimeric Antigen - immunology
/ Receptors, Chimeric Antigen - metabolism
/ Toxicity
/ Tumors
